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Abstract 
Microprocessor controlled lower-limb prosthetics provide many advantages over mechanical 
prosthetics such as, increased walking speed, decreased self-reported falls and stumbles, and 
boosted self-image. However, these devices remain out of the financial reach of the average 
prosthetic user. Interviews were performed with Hugh Herr, Bob Dzuranda, and prosthetists in 
the New England area in order to investigate a means to increase robotic prosthetic availability. 
It was determined that the prosthetics industry suffers from a slow billing code application 
process, Medicare-imposed fitness restrictions (on amputees that are likely to suffer from 
diabetes or obesity), insurance contracts that hurt prosthetist office profits, and private health 
insurance plans that restrict patients’ options. 
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Executive Summary 
In recent years, news and media outlets have applauded the advancements in robotic 
prosthetics, with special attention being paid to Dean Kamen’s DEKA arm and Hugh Herr’s 
PowerFoot BiOM.
1, 2
 Robotic prosthetics have been getting extra attention in the past decade due 
to the large number of amputees returning from Iraq and Afghanistan. According to the 
Congressional Research Service, the number of returning soldiers with full limb and/or partial 
amputation has climbed to over 1,600 as of 2010.
3
 This is only a small fraction of the U.S. 
population of amputees, however, which includes approximately 1.9 million individuals.
4
 
Despite the growing need for prosthetics that suit the active user's lifestyle, these devices still 
remain out of the financial reach of the average user. 
Many never look at the fine print of their private health insurance to see how much of the 
price of a prosthetic will be covered in case of an accident. Private insurers typically cover 
anywhere from 50-80% of the cost of a prosthetic, but some health insurance plans limit the 
insured member with payment caps that barely cover the cost or only allow the insured 1 
prosthetic for a lifetime. The price of these prosthetics is also variable, depending on what the 
insurance contract between the insurer and the prosthetist office stipulates. After interviewing 
prosthetists we found that microprocessor knees can cost anywhere from $33,000-$80,000 and 
robotic upper limb prosthetics can cost anywhere from $20,000-$120,000.
6
 As a result of these 
high prices and poor insurance coverage, stories where amputees are denied robotic prosthetics 
are all too common. For example, Robert Riiber, a bilateral transfemoral amputee (both legs 
amputated above the knee) was unable to purchase two C-Legs with the insurance he had. He 
reported falling a total of 25 times with his traditional prosthetics, once while he was crossing the 
street.
2
 He was forced to quit his job so he could become eligible for Medicare, since Medicare 
covers 80% of the cost of the device. 
To further add insult to injury, Medicare and other insurers require that the patient meet 
physical fitness requirements before receiving a lower limb robotic prosthetic. The patient is 
asked to perform a serious of tasks, as shown in Table 10 of the Appendix, and is diagnosed a 
functional level, or “K Level.” Only the highest two K Levels, K3 and K4, are eligible to receive 
a robotic lower limb prosthetic, which excludes a large portion of elderly or diabetic patients, 
who make up the majority of lower limb amputations. These physical restrictions keep K2 Level 
patients from receiving microprocessor knees, despite the fact that a report from the Veteran’s 
Affairs showed that K2 Level amputees were capable of increasing their activity level to K3 with 
the use of a robotic prosthetic. The interview results from the prosthetist interviews supported 
this claim, since 4/5 prosthetists answered that some of their patients who don’t use a robotic 
prosthetic would benefit from one. Of the four that said their patients would benefit from a 
robotic prosthetic, two said that K2 Levels should be granted access to robotic prosthetics. 
Hugh Herr was interviewed in order to gain an insight from a prosthetic designer’s point 
of view. Herr, who wears two powered ankle prosthetics himself, acknowledged that health 
 4 
 
insurance companies are reluctant to pay for devices that they deem not “medically necessary.” 
Herr claimed that health insurance companies would be more willing to pay for robotic 
prosthetics if they understood that they would actually be saving money because microprocessor 
controlled prosthetics prevent the patient from suffering from repeated falls and long-term 
related injuries. For example, the development of knee or hip problems from walking incorrectly 
could cost $80,000-$150,000 to fix with surgery (Analysis of Assembly Bill in the Appendix). 
However, since robotic prosthetics are still relatively new, there are no long term studies 
available to assert this claim to health insurance companies. 
After interviewing Bob Dzuranda, president of the prosthetic-fitting company Biometrics, 
it was discovered that most private insurers do not reimburse prosthetist offices as much for 
prosthetics as Medicare does, and that these reimbursement rates are decreasing. Private insurers 
also typically set their reimbursement rates as percentages of what Medicare pays. This makes it 
difficult for prosthetists to sell expensive microprocessor controlled prosthetics and in some 
cases prosthetist offices cannot accept a patient’s health insurance if the insurance company’s 
reimbursement rates are too low. Proposed prosthetic parity laws could fix this, however, by 
ensuring that private insurers reimburse prosthetist offices the same amount that Medicare does. 
In addition to fitness restrictions and low reimbursement rates, the prosthetics industry 
suffers from a lack of competition. Ottobock and Ossur are the manufacturers of the two most 
popular microprocessor controlled knees, the C-Leg and the Rheo Knee. Since these companies 
have very little competition, it is possible for them to sell the devices at higher prices without 
worrying about losing their customer base.  
Finally, the system that is in place to create new billing codes for prosthetics is slow. This 
discourages prosthetists from selling newer prosthetics, since offices that use the improper 
billing code are subject to Medicare audits. One of the major flaws in the billing process, is that 
new devices must complete three months of marketing before they can receive a new billing 
code. A need for a new billing code must also be recognized by Medicare, Medicaid, or a 
national private insurance company. If a device does not receive a billing code of its own, it is 
usually billed using a combination of older codes. In Medicare Region A, prosthetists must use 
the same billing codes for a C-Leg Genium as a C-Leg, even though a Genium is twice the cost 
of a C-Leg. Since the billing codes are the same, the prosthetist office gets reimbursed the same 
amount of money by the patient’s insurance, which discourages prosthetists from offering the 
newer device.  
Reduced physical restrictions for lower limb amputees, parity laws, and billing code 
application reform have the potential to increase the number of robotic prosthetic users and grant 
amputees a healthier, more active lifestyle.  
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Background 
The purpose of this section is to familiarize the readers of this report with the 
complexities of the amputee population and the prosthetic Industry. Our conclusions and 
discussion topics are partly based on the information that can be found in this section, so it may 
be important to understand the information in this section to understand the discussion topics 
later in the report. 
Amputation Statistics 
According to the People with Amputation Speak Out study, which was conducted in 2006 
in a collaborated effort between the Limb Loss Research and Statistics Program and the Amputee 
Coalition of America there are nearly 1.9 Million individuals living with limb loss in the United 
States of America.
7
 Approximately 185,000 Americans undergo the amputation of a limb each 
year.
7
 Figure 1, below, is an analysis of amputations in the United States by location of 
amputation. Figure 2, on the next page, is an analysis of amputations by the primary cause for the 
necessity of an amputation. 
 
Figure 1: Amputation by Location16 
Finger/Hand 
2.42% 
Below Elbow 
3.15% 
Above Elbow 
5.04% Bilateral Upper 
0.84% 
Toe/Foot/Ankle 
1.47% 
Below Knee 
38.87% 
Above Knee 
38.24% 
Bilateral Lower 
9.98% 
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Figure 2: Amputation by Cause16 
 
According to the People with Amputation Speak Out study, the number of trauma related 
amputees per year has been steadily decreasing due to advancements in treatment.
7
 According to 
Robert Swift, PhD, MD, associate chief of staff for research at the Providence Veterans Center, 
“People are surviving injuries that formerly were fatal [because of advances in battlefield 
medicine and armor]."
8
 Additionally, there has been an increase in the number of vascular 
disease, especially diabetes, related amputations per year
7
, and up to 55% of diabetic amputees 
require the amputation of the second leg within three years of the first amputation.
4
  
Also interesting to note, African Americans are 1.5 to 3.5 times more likely to undergo 
amputation, and Hispanic Americans are 3.6 times more likely to undergo amputation than white 
Americans. These differences may be due to the large number of Hispanic and African 
Americans living with diabetes and other vascular diseases.
7
  
Vascular Disease 
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Diabetes, 10.20%) 
Trauma 
47.70% 
Cancer 
12.50% 
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7.30% 
Infection 
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Why Microprocessor Controlled Prosthetics? 
 Microprocessor controlled prosthetics perform significantly differently than mechanical 
prosthetics. Unlike traditional knee prosthetics, microprocessor controlled knee prosthetics can 
“sense” when to apply resistance, which gives the user much greater stability. A typical variable 
friction knee may apply resistance during the stance phase (when the leg in question touches the 
ground), but during swing phase (when the leg is off the ground) the prosthetic joint straightens 
at a constant rate. As a result, the user is forced to adjust his/her gait to the device. In addition, 
since traditional prosthetics does not actively sense when to apply resistance, the device is not 
suited for preventing falls or for making quick changes in walking speed. This especially applies 
to single axis mechanical prosthetics, which may apply constant friction or have a locking 
mechanism, but otherwise they provide no resistance during stance phase.
9 
            The two most popular microprocessor controlled prosthetics on the market are 
Ottobock’s C-Leg and Ossur’s Rheo Knee. These prosthetics utilize microprocessors and sensors 
to determine when to provide resistance and when the knee should swing forward. The Rheo 
Knee uses a magnetorheological fluid between metal plates to provide resistance. When the heel 
strikes the ground, the sensors instruct the microprocessor to send a current through the 
magnetorheological fluid, which causes the knee to resist bending. The benefit of this system is 
that the knee freely swings forward when the leg is in the swing phase, which reduces the user’s 
energy expenditure. The downside is that the leg does not provide any resistance until the 
prosthetic detects that the heel has struck the ground. The C-Leg is a hydraulic microprocessor 
knee. When there is no current running through it, it functions like a normal hydraulic prosthetic, 
which gives the user added stability in case the battery dies unexpectedly. The onboard 
microprocessor controls tiny valves, which open and close to affect the resistance in the knee 
joint. It’s important to note that these are not powered prosthetics, like the PowerFoot BiOM is. 
This means that the C-Leg and Rheo Knee do not provide any extra force to help propel the user. 
The battery onboard each prosthetic merely controls an electronic braking system that gives the 
patient more stability. The downside to this is that someone using a C-Leg or Rheo Knee 
expends more energy walking than the average able-bodied individual. 
 "Comparison of Non-microprocessor Knee Mechanism versus C-Leg on Prosthesis 
Evaluation Questionnaire," a study conducted by the Department of Veteran's Affairs published 
in November 2008, compared the performance of non-microprocessor knee mechanisms 
(NMKM) to the performance of the Ottobock C-Leg. Nineteen above knee amputees wore a 
mechanical prosthetic for 90 days and then wore a C-Leg for 90 days. The subjects then reported 
the total number of times they thought they were going to fall or actually fell. These responses 
were used to determine the number of patient “stumbles” or “falls” as shown in Table 1. The 
subjects were also given the Prosthesis Evaluation Questionnaire (PEQ) to evaluate the prosthesis 
function and the subject’s prosthesis-related quality of life.8  
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 The prosthetic function was also evaluated based on the walking speeds of the subjects. 
Each subject was instructed to walk at either a self-selected walking speed (SSWS) or his/her 
fastest possible walking speed (FPWS) and the time it took them to cross specific distances was 
recorded.  
 
 
Table 1: C-Leg vs. Non-Microprocessor Knees8 
 
As Table 1 shows, there was a statistically significant improvement in all categories when 
the subject switched to the C-Leg. Self-reported stumbles decreased by 59% and self-reported 
falls decreased by 64%. There was also a 21% decrease in the amount of time it took the subjects 
to traverse 38m of uneven terrain. Microprocessor knees outperform standard above knee 
prosthetics walking speeds and provide the user with greater stability, resulting in fewer injuries.  
After the study was completed, the subjects were given the option to keep the C-Leg or 
return to their previous NMKM. Fourteen out of the nineteen (74%) subjects preferred the C-Leg 
and five subjects said they would rather return to their NMKM. Some of the reasons why the 
subjects refused to accept the C-Leg were that it was too expensive (even though it would have 
been free) and that it didn’t have the same cosmetic options as other prosthetics. 
Microprocessor knees provide the user with a greater sense of stability and they help 
prevent future injuries that could stem from the use of a poor prosthetic. For example, the 
development of knee or hip problems from walking incorrectly could cost $80,000-$150,000 to 
fix with surgery. Amputees may also suffer from wrist, elbow, and shoulder problems from 
crutch overuse, which can cost $7,500-$25,000 to correct, according to the Analysis of Assembly 
Bill in the Appendix. The C-Leg and other microprocessor knees are superior to traditional 
prosthetics in that they provide users with increased stability, increased walking speed, and an 
increased desire to ambulate. Microprocessor knees provide users with a healthier lifestyle and 
have the potential to prevent future medical bills.  
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HCPCS Level II Codes (L-Codes) 
 In order to facilitate the billing process, Medicare assigns billing codes for medical 
procedures, diagnoses, durable medical equipment, etc. The Healthcare Common Procedure 
Coding System (HCPCS) was established for this purpose.  The HCPCS is divided into two 
categories: HCPCS Level I and HCPCS Level II. HCPCS Level I codes are used to identify 
medical services and procedures furnished by physicians and other health care professionals. 
Since HCPCS Level I codes are not used for the billing of prosthetic devices, they will not be 
discussed further in this report, but more information on them can be found at 
(http://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/HCPCS_Coding_Questions.html). 
Level II of the HCPCS is a standardized coding system that is used to identify products 
and services not included in HCPCS Level I. These products and services include, but are not 
limited to, ambulatory services, durable medical equipment, prosthetics, orthotics and supplies 
(DMEPOS). The Level II HCPCS codes were established in order for Medicare and other 
insurers to submit claims for services, supplies, and equipment that may be provided to a patient 
outside of a physician's office (in order to cover prosthetist's fees, for example.) Prosthetic 
procedures are listed in the HCPCS Level II codes from code L5000-L9999 and are commonly 
referred to by prosthetists (or others in the prosthetics industry) as “L-Codes.”  
In order to establish these codes, Medicare contracts an outside company to assign billing 
codes to new devices. Noridian Systems has been the Pricing, Data Analysis and Coding 
Contractor (PDAC) for Medicare since it took over the coding duties from Palmetto GBA in 
2008.)  As the coding contractor for Medicare, Noridian Systems reviews billing code 
applications and revisions.
10 
If a new prosthetic device is invented, and it functions differently than any other 
categorized device, then a new billing code is required before Medicare or other insurers will 
cover the device. Anyone can send an HCPCS Level II code application in order to revise an 
existing L Code or to create a new one. The HCPCS Code Addition/ Revision Application Form 
can be found in the appendix. Anyone can send in an application, but if the applicant is not the 
manufacturer of the device, he must get the manufacturer to authorize the submission. The 
application process itself can be quite lengthy, especially if the medical device requires FDA 
approval, but thankfully for manufacturers, prosthetic devices are FDA Class II Exempt and do 
not require pre-market approval.   
Once the application is accepted, it must be approved. The application approval process 
is fairly arduous in order to prevent unnecessary billing code additions or revisions.  Figure 4 in 
the Appendix shows the steps that must be taken before a proposed addition or revision is 
accepted. A closer look at the HCPCS Decision Tree reveals that National Programmatic Need 
is required in order for a code to proceed to Tier II Categorization. National Programmic Need is 
also necessary in order to create a new code, use a miscellaneous code, or use an existing code as 
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a substitute. The HCPCS defines National Programmic Need as “At least one insurance sector, 
public (Medicare or Medicaid) or private (commercial insurers) identified a program operating 
need to separately identify the item and that need is common across the sector, (i.e., nationally, 
as opposed to one or a handful of individual insurers or states). Does not apply if item 
identification is statutorily required.” Essentially, an HCPCS Level II Code cannot be assigned to 
a new device unless Medicare, Medicaid, or a national private insurance company deems a new 
code necessary.  
Another requirement for the code revision/addition to get approved is that the device 
needs to meet volume and marketing criteria. The HCPCS defines volume and marketing criteria 
as there being “sufficient claims activity or volume in 3% of the affected population, as 
evidenced by 3 months of marketing activity.” This is necessary to demonstrate that a new or 
revised HCPCS Level II code is worth the administrative costs involved to change the existing 
code set. The marketing performed prior to code revision/addition is advantageous for the 
HCPCS administration, but not for prosthetic manufacturers.  
Because the billing code categorization process is so lengthy, it is not uncommon for 
older billing codes to be used for newer devices. For example, Ottobock recommends that 
prosthetist offices use a combination of previously adopted C-Leg billing codes to bill the new 
C-Leg Genium. However, this can have undesired consequences for the prosthetist office if 
Medicare or a private insurer deems the billing code as inappropriate. However, this does not 
prevent all prosthetists from selling newer devices without L-codes as we discovered. The 
PowerFoot BiOM does not have an L Code, as reported by Hugh Herr, but this does not stop 
prosthetist offices that are PowerFoot certified from selling the device.  
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Prosthetist Company Insurance Contracts 
The amount that Medicare or a private insurance company reimburses a prosthetist office 
is known as a fee schedule. Medicare utilizes the HCPCS Level II codes to determine how much 
it will reimburse the prosthetist’s office for the goods and services it renders to Medicare 
recipients.  For example, Medicare will reimburse the prosthetist’s office $31,267 for a C-Leg 
with the Pyramid Top (the HCPCS Level II codes for which are, L5828 + L5845 + L5848 + 
L5856 + L5930) sold in Connecticut in 2012. This means that the patient would then be charged 
$31,267, 80% of which would be covered by Medicare, leaving the patient with a bill for $6,253. 
The amount that Medicare reimburses the prosthetist’s office varies from state-to-state in order 
to compensate for differences in cost of living (the national average reimbursement amount for a 
C-Leg with Pyramid Top is $30,864.56).
11
  
 When a prosthetic-fitting company or office wishes to sell a prosthetic or orthotic to a 
patient, that company or office first makes an arrangement with the patient’s health insurance. 
The private insurance company makes a contract with the prosthetist company to determine the 
amount of money that the private insurer will reimburse the prosthetist company for each piece 
of durable medical equipment that the company offers its patients. The private insurer usually 
uses the L-Codes established by Medicare in order to facilitate the billing process. The insurance 
company and prosthetist company negotiate to determine how much money the private insurer 
should pay for each L-Code. For example, a private insurer may agree to reimburse the 
prosthetist company a large amount of money for orthotic shoes, as long as the private insurer 
can make discounted reimbursements for prosthetics.  
 When the insurance contract is made, the private insurer usually decides to set its 
reimbursement rate in relation to Medicare’s. For example, a private insurer may agree to set its 
reimbursement amount as 10% less than what Medicare would reimburse for the same L-Code. 
This kind of negotiation may be beneficial to some insured members, since the overall price of 
the device is lower, but usually it just makes the device more difficult for the prosthetist’s office 
to sell. For example, United HealthCare wished to reimburse Biometrics, a prosthetic-fitting 
company, 45% less than what Medicare reimburses for prosthetics. United HealthCare would 
then only reimburse Biometrics $17,197 for a C-Leg that Medicare would reimburse $31,267 for. 
According to Bob Dzuranda, the president of Biometrics, this was simply not enough money to 
compensate for the price that his company pays to buy the device from Ottobock. He was 
uncomfortable specifying how much money his company pays Ottobock for each C-Leg, 
however. Since United HealthCare reimbursements are so low, Biometrics is unable to provide 
in-network service to United HealthCare members.
12
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Health Insurance Coverage of Prosthetic Devices 
Several example medical insurance plan quotes from a small selection of insurers, 
including Medicare, can be found in the appendix. This section of the report will explain these 
quotes and how they affect the out-of-pocket expense of a range of insured amputees.  
The coverage of robotic prosthetics by private and government insurers alike falls into 
the category of Durable Medical Equipment (D.M.E). For this category of medical coverage the 
coinsurance, the coinsurance maximum, the out-of-pocket maximum (stop loss), and any specific 
maximums on D.M.E can all affect how much the user of a robotic prosthetic must pay out of 
pocket to receive their device. The aforementioned expenses vary depending on the monthly 
premium and deductible that are selected by the insured policy holder in the policy acquisition 
process. Using the medical insurance quotes found in the appendix, several examples are given 
below to show the relationship between the above costs and the amount a patient must pay out of 
pocket. 
For the sake of ease, say patient X is a thirty-year-old non-tobacco-using male, is 
assessed to be K-level 4 (An explanation of K-levels can be found in the next section of this 
report), and his prosthetist recommends the robotic prosthetic “Y” which conveniently costs 
exactly $100,000.  
If patient X is able to afford a low deductible, high monthly premium variant of Anthem 
Blue Cross Blue Shield’s “Premier” plan (found in the appendix), his out of pocket expense 
towards his robotic prosthetic can be relatively low. After first paying the deductible of $500, he 
is then responsible for the coinsurance of 20% of the remaining cost. This coinsurance is limited 
by the coinsurance maximum which in this case is $3000. Since 20% of $99,500 ($19,900) is 
greater than the coinsurance maximum, patient X is responsible for only an additional $3000. 
This means that patient X will end up paying only $3,500, which is the out-of-pocket maximum 
(as seen in Table 7 in the appendix). The downside is that patient X is quoted to be responsible 
for a $3,752 premium expense per calendar year ($312.56 per month), which most people find 
unnecessary or unaffordable.
13 
If patient X chose, instead, a low premium, high deductible variant of the same “Premier” 
plan offered by Anthem Blue Cross Blue Shield, his out of pocket expense is much different. 
First, as before, he must pay the deductible of $10,000 in this case. The coinsurance for this plan 
is 0% and the coinsurance maximum is $0, so patient X’s out-of-pocket expense is the out-of-
pocket maximum of $10,000. The premium for this plan is quoted much less at $1448.88 per 
calendar year ($120.74 per month).
13
 
 
 
 13 
 
If patient X decided the more affordable high premium, low deductible variant of the 
“SmartSense” plan offered by Anthem Blue Cross Blue Shield was right for him, his out-of-
pocket expense will be different still. After paying the deductible of $750, he would be 
responsible for the coinsurance of 30% of the remaining cost up to the coinsurance maximum of 
$4000. His total out-of-pocket expense will equal the out-of-pocket maximum of $4,750. His 
premium is quoted at $2976.96 ($248.08 per month).
13 
With the low premium, high deductible variant of the “SmartSense” plan offered by 
Anthem Blue Cross Blue Shield. Patient X, like before, will first be responsible for the 
deductible of $12,000 in this case. The coinsurance for this plan is 0%, so patient X’s out-of-
pocket expense will be the out-of-pocket maximum of $12,000. The premium for this plan is 
quoted at $1025.76 per calendar year ($85.48 per month).
13 
If patient X was insured under Medicare Part B, like before, he would first be responsible 
for the deductable of $140. He would then be responsible for the 20% coinsurance for the 
remaining $99,860. Since Medicare does not have a coinsurance maximum, patient X must pay 
an additional $19,972 bringing the total out-of-pocket expense to $20,112.
14 
Many Insurance companies have a cap per calendar year specific to the D.M.E category 
of medical coverage that is befitting to such equipment as blood testing strips for diabetics, but 
that far undershoots the cost of modern robotic prosthetics. For instance, the three example plans 
from Aetna (Table 5 in the Appendix) all have a cap of $2000 per calendar year for durable 
medical equipment. This means that if patient X is insured by one of these plans, he is 
responsible for $98,000 towards the $100,000 prosthetic. Furthermore, if patient X is a diabetes 
sufferer, he will have already used part of his $2000 cap on his testing and other diabetes related 
supplies.
15
  
The out-of-pocket maximums for a family insurance plan can be more than double those 
of an individual plan. If patient X is a member of a family that is insured collectively with a 
family plan, the total out-of-pocket expense can be higher than in the previous examples.  
 
Family Plan Variants 
Medical  
Insurance Plan: 
High Premium, 
Low Deductible 
Low Premium, 
High 
Deductible 
Premier Plan $7000 $20,000 
SmartSense Plan $9,500 $24,000 
Table 2: Examples of Out-Of-Pocket Expenses with a Family Plan13 
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Table 3: Examples of Out-of-Pocket Expenses with an Individual Plan13 
The prices Tables 2 and 3 are the estimated out-of-pocket expenses for a 30 year-old non-
tobacco-using male for a hypothetical $100,000 robotic prosthetic called the “Y”. They can be 
used to easily see the relationship between the family and individual plan expenses. Although 
these example family plans all estimate the out-of-pocket expense to be twice the out-of-pocket 
expense for the corresponding individual plans, this is not always the case. Many family plans 
offered by other insurers can vary independently from their individual plan counterparts. 
 The numbers used in this section are meant only as an example to show how the out of 
pocket expense for a robotic prosthetic vary based on the above defined terms. Actual out of 
pocket expenses can be higher. For instance, as seen in the Amputee Survey Results section of 
this report, one amputee reported to have paid $30,000-$35,000 out of pocket on his C-Leg. He 
also reported that the price of the device would have been greater than $80,000 without insurance 
and that the insurance covered 60-70% of the cost of the device. 
 There is another limitation in many existing insurance policies that has yet to be 
discussed. For some policies there is a limit on the number of prosthetic or prosthetic related 
devices that can be purchased per calendar year. This limitation has serious repercussions. For 
instance, Robert Riiber, a bilateral transfemoral amputee was unable to purchase two C-Legs 
with his insurance plan as mentioned in the Executive Summary section of this report. Patients 
who suffer the loss of multiple limbs in a single year can run into problems with their insurance 
coverage. As seen in the Health Insurance Appeals section of the Prosthetist Survey Results, 
prosthetists sometimes have to fight denial after denial with several appeals before an insurance 
company finally accepts a claim. Even patients who lose only a single limb have trouble with 
prosthetic caps imposed by insurance companies. Often times a temporary prosthetic is used for 
the first several months after an amputation to allow the swelling in the residual limb to subside 
before switching to the permanent prosthetic as seen in the Difference in Approach subsection of 
the Prosthetist Interview Questions and Answers section of this report.. If the temporary 
prosthetic is bought with an insurance plan that only covers a single device per calendar year, the 
amputee may have to wait a full year before receiving their permanent device. Additionally, if a 
single part on the prosthetic were to break, this policy may inhibit an amputee from receiving 
replacement parts in a timely manner. Some insurance companies even limit the insured member 
to one prosthetic per lifetime, which is unreasonable with the amount of damage a prosthetic 
endures from everyday use. 
  
Individual Plan Variants 
Medical  
Insurance Plan: 
High Premium, 
Low Deductible 
Low Premium, 
High 
Deductible 
Premier Plan $3500 $10,000 
SmartSense Plan $4,750 $12,000 
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An Explanation of Level II Modifiers (K-Levels) 
The demographic of amputees ranges from young, fit soldiers coming back from overseas 
to elderly and overweight diabetes sufferers. Naturally, some of these patients seek the newest 
and best technology prosthetics in order to return their bodies to the most functional state 
possible, but this is not the case for every amputee. In many cases, a traditional device is 
preferable over a robotic or myoelectric device due to simplicity, ease of use, and/or cost 
effectiveness.  
The Level II or “K-modifiers” system is a well-tested and validated tool that was 
developed by Medicare as a means of classifying amputees by their level of activity.  As a guide 
to determine what type of prosthetic would be best for their patients, prosthetists use the 
“Amputee Mobility Predictor Assessment Tool” (found in the appendix) for assessing a patient’s 
activity level or “K” level. For lower extremity prosthetic users there are five K levels ranging 
from K0, the least physically active patients, to K4, the most physically active patients. A 
description of each K level can be found in Table 9 of the Appendix along with the assessment 
tool. 
 Many private insurance companies use the Level II Modifiers to determine which devices 
they will cover for each of their clients. The K level of a patient determines the subgroup of L-
codes and therefore the selection of prosthetic devices that their insurance company will cover. 
For instance, the insurance of an elderly patient whom has been assessed as a K1 will likely 
cover only the most basic mechanical or aesthetic prosthetics. Respectively, the insurance of a 
young soldier whom has been assessed as a K4 will likely provide coverage for the most up to 
date technology available. Amputees of K levels K0 through K2 whom desire a robotic device do 
not receive coverage for such a device and must pay full price out of pocket. Even some 
pneumatic mechanical prosthetics are covered exclusively for K3 and K4 patients. 
In theory, the system works to provide the best and most cost effective treatment for 
patients by providing them with devices that neither exceed nor fail to meet their specific needs. 
As the system currently stands, patients whom have been assessed as K levels 2 and below 
cannot receive insurance coverage for robotic and myoelectric prosthetic devices. However, as 
seen in the Results section of this report, prosthetists from Next Step in Newton, Massachusetts 
and from NEOPS in New London, Connecticut expressed that robotic prosthetic coverage should 
be extended to patients deemed to have a “K Level” of 2. These patients have the potential to 
greatly benefit from the use of better technology prosthetics.  
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Parity Laws 
 Coverage of Prosthetic Devices  
As presented, SB 98 (2008), the Prosthetic Parity Act, would revise the requirements that a health 
insurer, a nonprofit health service plan, or an HMO (further referred to as “carriers”) would need to 
meet in providing coverage for prosthetic devices and orthopedic braces. The proposed changes are 
as follows:  
Section 15–820, Insurance Article, Annotated Code of Maryland, would be revised to mandate 
nonprofit health service plans that provide hospital benefits to provide benefits for orthopedic braces 
only. (Currently, Section 15–820 mandates nonprofit health service plans to provide benefits for both 
prosthetic devices and orthopedic braces).  
Section 15–843, Insurance Article, Annotated Code of Maryland, would be added as a new 
mandate. This would require carriers to provide the following:  
– For prosthetic devices, coverage and payment at least equal to that provided under federal laws and 
regulations for the aged and disabled  
– Coverage for the prosthetic device determined to be the most appropriate model that adequately 
meets the insured’s medical needs  
– Coverage for repair or replacement of a prosthetic device because of a change in the insured’s 
physical condition.  
 
While SB 98 does address benefits for orthopedic braces, the mandated benefit that needs to be 
offered by nonprofit health service plans is not changing. This report will focus on the impact of 
mandating prosthetic devices by carriers.  
Following is a discussion of the medical, social, and financial impacts of this proposal. 
Figure 3: An Excerpt from Maryland’s SB 98 (2008), Prosthetic Parity Act (amputeecoalition.org)17 
The above figure is an excerpt from SB 98 (2008), the Prosthetic Parity Act. The rest of 
the act can be found on the amputee coalition site and focuses mainly on defining the reasoning 
and necessity for the act.  More on that topic can be found in the “Need for Parity Laws” section 
of this report. As seen above the act will require all private insurance providers to provide a level 
of coverage that is at least on par with the coverage provided by government programs for the 
aged and disabled. This mandate will have a noticeable effect on the prosthetic industry.  
The Amputee Coalition of America performed an analysis for the Virginia Special 
Commission on Mandated Health Benefits in order to better predict some of these effects. This 
analysis can be found in the Appendix under “Analysis of Assembly Bill 2012-Amended: 
Orthotic and Prosthetic Devices” and is discussed in the “Need for Parity Laws” section of this 
report.  
Parity laws will directly affect the way prosthetic companies make contracts with 
insurers. Currently prosthetic company insurance contracts work as they are described in the 
same-named section of this report. The parity laws will force insurance companies like United 
HealthCare to recognize the full Medicare approved value of prosthetic devices and reimburse 
prosthetic offices accordingly. This will allow more amputees to have access to robotic 
prosthetic devices as their prosthetist will be able to accept their insurance.  
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Donation 
 
 It is possible to donate one’s old or unused prosthetic to someone else in need. This can 
be done one of two ways. The prosthetic can be donated to a foundation like Limbs for Life 
where the prosthetic, or its components, will be given to someone in financial need or shipped 
overseas.
18
 If the individual knows who he would like to donate the prosthetic to, then he can 
contact the health insurance of the person receiving the device.
19
 The problem, however, is that 
the warranties on robotic prosthetics typically only cover the device for 3 years, and the devices 
usually break within a year or two after this. Since the devices expire quickly, are expensive, and 
are only given to highly active users, the prosthetic usually breaks before it can be donated.   
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Methodology  
 With our goal of increasing the availability of robotic prosthetics in mind, our project 
team decided the best course of action for acquiring data would be to create a set of 
interview/survey questions. We first broke down our intended sources into four main categories. 
These categories include amputees, prosthetists, prosthetic designers/manufacturers, and 
insurance companies since these were the sources from which we believed we would be able to 
acquire the most pertinent data. We developed four corresponding lists of questions, one for each 
subcategory. These questions and their resulting answers can be found in the Appendix and in 
the Results section of this report. 
 At the same time, we also began researching for the Background section of our report. 
We utilized the Amputee Coalition of America and the Department of Veterans affairs to find the 
studies, statistics, and data presented in this report. Interviews with prosthetists and with Bob 
Dzuranda, the president of Biometrics, helped to further expand our understanding of the 
prosthetic industry. In order to understand the role of health insurance in the prosthetic industry, 
we first started by calling several insurance companies and asking them basic questions about 
their policies and coverage of durable medical equipment. We then acquired health insurance 
quotes using the online tools provided by Aetna, Assurant, Anthem Blue Cross Blue Shield, and 
Medicare. 
 Before leaving each prosthetist’s office, we first asked if it would be okay if we posted a 
flyer (found in the Appendix) that asks for robotic prosthetic users to complete the Amputee 
Survey (also found in the appendix). This method of acquiring data was not effective, however. 
After several weeks with no responses to the survey, we took more drastic measures. We posted 
the survey on the Amputee Coalition’s Facebook page where amputees frequently visit to post 
about personal milestones, troubles, and to support fellow amputees. We contacted the VA 
outpatient center in Worcester, but they were unable to help due to confidentiality concerns. We 
contacted the prosthetics division of the VA center in West Roxbury as well, but they did not 
return our calls. We also got the survey posted to dav.org by contacting the DAV. These 
additional measures were also insufficient at acquiring robotic prosthetic user data. In the end, 
we were only able to acquire two responses to our Amputee Survey. These responses can be 
found in the Amputee Survey Results section of this report. 
 Since the interviews were performed face-to-face the prosthetists were able to answer 
questions freely and clarify terminology with which we were unfamiliar. However, arranging 
face-to-face interviews was difficult and time-consuming. It was difficult to arrange interviews 
during normal business hours, since this conflicted with the group members' course schedule and 
of the prosthetists offices that were called, only a few actually returned our phone calls or 
arranged interviews. 
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Results 
In this section we will state the findings of our project including the results from our 
interviews and surveys. 
Prosthetist Survey Data 
 Interviews were arranged with prosthetists over the phone and then held in person at the 
prosthetist’s office, with the exception of the prosthetist from Hanger Orthopedic Group, who 
was interviewed over the phone. Prosthetists from Next Step, New England Orthotic and 
Prosthetic Systems (NEOPS), and Hanger Orthopedic Group were interviewed. The purpose of 
the interviews was to gather information about the cost of prosthetic devices, patient satisfaction, 
and opinions and anecdotes from the prosthetists themselves. It should be noted that prosthetists 
that fit a large portion of their patients with electronically-controlled prosthetics were more 
familiar with the prices of robotic prostheses.  
Abbreviations: 
A few abbreviations will have to be understood in order to interpret some of the answers: 
BK-Below Knee 
AK-Above Knee 
UE-Upper Extremity 
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Prosthetist Interview Questions and Answers 
The responses from the prosthetists were recorded by taking notes during the interviews. The 
following answers are accurate, but the prosthetist’s actual answers have been abbreviated. 
Experience and Customer Base: 
1. How long have you been working as a prosthetist? 
 
Worcester, MA- NEOPS: 22 years 
20 
Branford, CT-NEOPS: 13 years
21 
Newton, MA-Next Step: 26 years
22 
Worcester, MA-Hanger Orthopedic Group: 2 years
17 
New London, CT-NEOPS: 17 years
6 
 
2. Approximately what percentage of your limb-loss patients use robotic prosthetics? 
 
Worcester-NEOPS:  
4%-5% 
Branford-NEOPS: 
20% of above knee 
<5% of Below Knee amputees 
5% of Upper Extremity amputees 
Total: 15% 
Newton-Next Step:  
Reported that they treated a lot of K3 and K4 patients 
Above Knee: 50%  
Total: Unsure 
Worcester-Hanger:  
Reported that not many of the patients are above knee amputees 
5% 
New London-NEOPS:  
5% 
Average (Newton Excluded):  
7.50% 
Average (Newton Included): 
16.00% 
 
3. Approximately what percent of your patients choose robotic prosthetics? 
 
Worcester-NEOPS: Mostly young patients will choose robotic prosthetics. Older patients prefer 
something comfortable for low activity. 
Branford-NEOPS: 100% of AK amputees try to receive one, but only about 20% of AK 
amputees actually receive one. 
Newton-Next Step: Tries to get a microprocessor controlled knee for all AK amputees. 
Worcester-Hanger: 5% 
New London-NEOPS: 5% 
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Patient Satisfaction 
4. Do your patients prefer a traditional [non-electronic] prosthetic over a robotic 
prosthetic? Why? 
 
Worcester-NEOPS: Most patients receive traditional. Younger patients want robotic. 
Branford-NEOPS: Unsure. 
Newton-Next Step: Patients prefer robotic. 
Worcester-Hanger: No one prefers traditional. 
New London-NEOPS: Yes. Patients prefer an electronic or microprocessor controlled prosthetic. 
 
5. What percentage of patients who switch from traditional prosthetics to robotic 
prosthetics are more satisfied with the robotic device? 
 
Worcester-NEOPS: Rarely do patients switch from traditional prosthetics to robotic ones, unless 
they’re switching from a temporary prosthetic to a robotic one. 
Branford-NEOPS: Depends on individual. Some reject the robotic prosthetic.  More are 
amazed by what they are now capable of. Treated a patient who used a hip-down traditional 
prosthetic for 60 years and converted him to a robotic prosthetic in 4 months. 
Newton-Next Step: 100% are more satisfied with a robotic device. The only reason to keep a 
traditional device handy is in the case of going to the water or the beach or another equally 
hazardous location for electronics. 
Worcester-Hanger: 99.90% 
New London-NEOPS: Patients are more satisfied with robotic prosthetics. If you were to allow 
a patient to adjust to a C-Leg and then gave him a traditional hydraulic leg, he would fall right on 
his butt. 
6. Do you think some of your patients who do not use a robotic prosthetic would 
benefit from one? 
 
Worcester-NEOPS: Probably. Most patients treated are diagnosed as low K Levels and are not 
offered robotic prosthetics 
Branford-NEOPS: Yes. 
Newton-Next Step: Yes. K2 levels should be able to get robotic prosthetics. 
Worcester-Hanger: Yes. Usually low K levels don't get offered robotic prosthetics, but if the 
patient requests one, the prosthetists' office will try to get the patient’s health insurance to 
comply with the request. 
New London-NEOPS: Yes. K2s should get approved for robotic prosthetics. About 50% of the 
patients could be wearing a better prosthetic. Most of the time patients are not offered 
microprocessor controlled knees because they are not a K3 or K4 or because they do not have 
the funds to pay for a robotic prosthetic. 
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7. Overall, would you say that your patients are pleased with the functionality of their 
prosthetic? (traditional or robotic) 
 
Worcester-NEOPS: Patients whom are new to the world of prosthetics tend to be pleased with the 
functionality of their prosthetic, but longer term patients tend to have higher standards. 
Branford-NEOPS: Yes, if not they come back for a refitting. 
Newton-Next Step: I’ve received no complaints for robotic prostheitcs. Traditional prostheitc users 
have stability issues. 
Worcester-Hanger: Yes, although patients with microprocessor controlled prosthetics are more 
pleased. 
New London-NEOPS: Yes 
 
8. For the patients whom are displeased with the functionality of their prosthetic, do 
you believe there is a prosthetic with which they would be more pleased? 
 
Worcester-NEOPS: Displeased patients usually aren't satisfied because it's not their real limb. 
Branford-NEOPS: Probably, most of the time it's a comfort issue or an attitude issue 
Newton-Next Step: Most issues are with socket fit. 
Worcester-Hanger: Yes. 
New London-NEOPS: Most of the time it’s a comfort or attitude issue. 
 
9. Do robotic prosthetics have issues that the more traditional prosthetics do not suffer 
from? If so, what are they? 
 
Worcester-NEOPS: More parts, more problems. Certain robotic prosthetics have warranty 
clauses that require the devices to be shipped to the manufacturer for repairs. Patient uses a 
temporary (less functional and less comfortable) prosthetic in the meantime. Some prosthetic 
companies send out loaner units. 
Branford-NEOPS: Robotic prosthetics require more initial maintenance than a traditional 
prosthetic, since they require initial programming to match the patient’s gait. Don't see them in 
for repair much. Robotic prosthetics are heavier which creates more discomfort. Usually lasts 2 
years. Requires initial programming and maintenance. 
Newton-Next Step: Water resistance and high humidity are issues. Robotic prosthetics require 
an outlet to charge, but robotic prosthetics are pretty reliable on the most part. 
Worcester-Hanger: Yes, all need typical maintenance. Robotic prosthetics require prosthetists 
to receive more training. 
New London-NEOPS: You need to charge a robotic prosthetic. They don't break more than 
traditional prosthetics. 
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Cost to the Patient 
10. Do any of your patients have to settle for a less functional device due to cost? 
 
Worcester-NEOPS: Yes 
Branford-NEOPS: Yes. Very few. 
Newton-Next Step: Absolutely. Cost is always the final deciding factor. 
Worcester-Hanger: Yes. 
New London-NEOPS: All the time. It depends on the patient's insurance. Recommends patients get 
supplementary insurance to pay for the device. 
 
11. If so, approximately what percent? 
 
Worcester-NEOPS: A slim percent. 
Branford-NEOPS: Patients seldom have to pick a less functional device. It mostly occurs with 
the uninsured. 
Newton-Next Step: 25% 
Worcester-Hanger: Unsure. 
New London-NEOPS: Unsure. A majority of the patients treated could be wearing a better 
prosthetic. 
 
 
12. What are some prices of the devices you sell? 
 
Worcester-NEOPS: Limb Logic VS: $1,600 (electronic vacuum suspension system)  
Branford-NEOPS: BK prosthetics: $6,000-$15,000 (Propriofoot); microprocessor knees: 
$38,000-$52,000; Myoelectric $35,000; UE passive: $3,000-$5,000; cable driven: $6,000-
$12,000  
Newton-Next Step: Powerfoot BiOM: $75,000; i-Limb Pulse $45,000; C-Leg: $45,000 
Worcester-Hanger: Unsure. Prices range from $20,000 to 90,000 for the C-Leg Genium 
New London-NEOPS: BK: $10,000-$30,000; AK: $33,000-$80,000; AK powered: 
$120,000; UE: $20,000-$120,000;  
 
13. What are the some of the price ranges for the different types of prosthetic devices 
that you sell? 
 
Worcester-NEOPS: Preparatory BK prosthetic: $5,000    Vacuum pump suspension: $10,000 
Branford-NEOPS: See Response to Question 12 
Newton-Next Step: See Response to Question 12 
Worcester-Hanger: See Response to Question 12 
New London-NEOPS: See Response to Question 12 
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14. In your opinion, are these prices reasonable or unreasonable? 
 
Worcester-NEOPS: Reasonable with the amount of money that is spent on research and 
development. 
Branford-NEOPS: Reasonable. 
Newton-Next Step: Return on research and development is difficult. Funding is a large problem. 
Worcester-Hanger: Reasonable. The devices are expensive, but they're worth it. 
New London-NEOPS: Unsure. Insurance contracts are horrendous. Insurance companies are 
price fixing, essentially. Private insurance companies usually cover less of the price for a 
prosthetic than Medicare. This causes otherwise able-bodied and healthy people to quit work 
and go on disability in order to receive Medicare. 
 
Prospects for the Future 
15. With the decreasing price of technology in mind, do you think that robotic 
prosthetics will become available to the average user? 
 
Worcester-NEOPS: With the influx of service injuries there will be more amputees and therefore more 
demand for high quality devices (since service men are of the highest K level) and therefore prices will 
come down.  
Branford-NEOPS: More people will be able to get a robotic prosthetic, but the price will remain the 
same. 
Newton-Next Step: Prices will stay the same. The C-leg costs roughly the same as it did 14 years ago. 
Worcester-Hanger: Yes 
New London-NEOPS: Unsure with all the money that is spent on research and development. The 
government is gradually paying less for prosthetics. It's difficult for advancements to be made because 
engineers are forced to design a device that matches an existing billing code, or alternatively, design a 
device that is more functional, but more expensive. 
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Differences in Approach 
 
Worcester-NEOPS: Lower limb amputees usually start with a temporary prosthetic for the first six 
months after amputation. This allows the swelling to go down and for a proper socket fit to be made for 
the permanent prosthetic. If a patient’s robotic prosthetic breaks, then the prosthetic is sent back to the 
manufacturer and the patient uses a temporary traditional prosthetic if the manufacturer doesn’t send 
out a “loaner”. 
Branford-NEOPS:  Lower limb amputees are given a microprocessor knee as soon as possible, if 
eligible. The office keeps older, donated robotic prosthetics so that patients can walk with a robotic 
prosthetic while they await their permanent robotic prosthetic to be delivered. These “loaner” robotic 
prosthetics are also used if the patient’s prosthetic ever needs to be sent back to the manufacturer for 
repair. Spends extra time with the patients to get them accustomed to the device, even though it is not 
required.  
Newton-Next Step: Keeps “loaner” robotic prosthetics for patients to use in case theirs breaks.  
Worcester-Hanger: - 
New London-NEOPS: Recommends patients get supplementary insurance to pay for their prosthetic. 
 
 
Health Insurance Appeals 
Worcester-NEOPS: It’s not really common to have health insurance deny claims. However, there was 
one instance where a patient with diabetes was denied a passive ankle prosthetic. The gentleman had 
already had his left foot amputated earlier that year and he just had his right leg amputated above the 
knee. The prosthetist wanted to attach the same ankle prosthetic on the patient’s temporary AK 
prosthetic as the one he already had on his left leg. His health insurance did not think the ankle was 
“medically necessary” for a temporary leg. The prosthetist wrote the patient’s health insurance a letter 
explaining that the patient needed the two ankles to be identical for proper balance and health reasons. 
The health insurance approved the claim and covered the patient’s second ankle prosthetic. 
Branford-NEOPS: Usually sees 1-2 appeals per patient. Feels that it’s the health insurance companies’ 
job to deny claims and save money. 
Newton-Next Step: 80-90% of the requests for prosthetic payment go through the health insurance 
without having to send the insurance company an appeal. Before the payment request is made to the 
health insurance company a large document entailing the patient’s health history and need to ambulate 
is sent. This usually prevents companies from denying claims. 
Worcester-Hanger: - 
New London-NEOPS:- 
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Amputee Survey Data 
 
Table 4: Amputee Survey Questions and Responses 
Please specify your level of amputation. 
Above Knee 
Above Knee 
What is the name of the robotic prosthetic you use/have used? 
C-Leg 
c-leg 
Would you rather use a traditional prosthetic or a robotic one? 
Robotic 
Robotic 
Why? 
  It's hard enough wearing and walking with a Prosthetic leg, so why use a manual knee.  The only reason I 
could see would be because of cost. 
  the microprocessors in the knee are what gives relief to my good leg and allows me to have quality of life 
that I use to have. 
Are you pleased with the function of your robotic prosthetic? 
Yes 
Yes 
Why? 
It assists me in walking.  It's much better in terms of control and stability. 
I can do almost all of the things that I use to do, but just in different ways.  Plus it allows for my good leg to 
get a rest. 
Do you feel there is a prosthetic that would better suit your needs? 
No 
Yes 
If so, please give a description or the name of the prosthetic. 
  
Genium by Otto Bock 
Was price a major factor when choosing your robotic prosthetic? 
No 
No 
If so, how did it affect your decision? 
  
Most people it is, but I am lucky enough to have the financial needs to cover what insurance doesn't. 
What was the total cost of your robotic prosthetic? 
$55,000-$59,999 
>$80,000 
What was the total out-of-pocket expense for your prosthetic? 
$10,000-$14,999 
$30,000-$34,999 
What health insurance provider did you have when you purchased your prosthetic? 
Medicare 
Blue Cross 
Approximately what percent of the cost did your health insurance cover? 
70-80% 
60-70% 
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If you received any other financial aid, who provided it? 
If you received any other financial aid, how much of the cost did it cover? 
  
Received no other forms of financial aid 
On a scale of 1-5, was the price of your robotic prosthetic reasonable or unreasonable? 
4 
4 
What was the total out-of-pocket expense for your physical therapy? 
>$2,000 
>$2,000 
If you required physical therapy, what was the total cost? 
>$2,000 
>$2,000 
Approximately what percent of the cost did your health insurance cover? 
80-90% 
60-70% 
If you received any other financial aid, how much of the cost of physical therapy did it cover? 
Received no other forms of financial aid 
Received no other forms of financial aid 
How long is the warranty for your robotic prosthetic? 
3 Years 
3 Years 
What's the average amount of time you use a robotic prosthetic for before it needs to be replaced or 
repaired? 
Still using the first robotic prosthetic 
1 Year 
With the decreasing price of technology in mind, do you think that robotic prosthetics will become 
available to the average user? 
  No, if the insurance companies continue to play games with us they way they are, then forget it!  Do they 
actually think we enjoy missing a leg?  We have to jump through hoops to get things approved.  I'm a K4 
amputee and Medicare declines nearly every claim that is submitted for me.  It's a shame! 
 
  I personally do not.  If they do it will be in a time where I am no longer alive.  Insurance has always made 
amputees jump through hoops in order to get proper care.  Many insurance carriers do not even like to cover 
O&P expenses.  Some only offer 1 limb in a lifetime which is just impossible. 
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Interview with Hugh Herr24 
 Hugh Herr heads the Biomechatronics group at the MIT Media Lab and he is the founder 
and chief scientific officer of the prosthetics company iWalk. Hugh lost both of his legs below 
the knee in a hiking accident when he was 17 and has since devoted himself to rehabilitation 
engineering. We first met with Hugh Herr at the 2012 WPI Neuroprosthetics Symposium after 
his presentation on powered prosthetics, which he finished by bounding from one side of the 
stage to the other, showing off the amazing capabilities of his two powered ankle prosthetics. 
 Hugh reported that research and development for the PowerFoot BiOM, the latest robotic 
prosthetic from iWalk, cost approximately $25 million dollars, though it is likely that much of 
this bill was used for developing his company. During our discussion, Hugh emphasized his 
opinion that the issue with the high cost of robotic prosthetics cannot be solved by cutting costs 
at the developer’s end. Instead, designers should be striving for the designs that perfectly emulate 
natural human limbs. Hugh Herr refers to these emulating devices as “bionics.” If perfect human 
limb emulation were achieved, many of the expensive medical problems associated with long 
term limb loss and prosthetic use could be avoided, thus saving insurance companies money in 
the long run while enabling amputees to return to healthy and productive lifestyles. The 
“Analysis of Assembly Bill 2012-Amended: Orthotic and Prosthetic Devices” (which can be 
found in the appendix) addresses some of the potential long term complications that prosthetic 
users face. If studies were conducted that highlighted the correlation between so-called “bionics” 
and a lower lifetime medical expense, insurance companies would be more than willing to fund 
their clients in the interest of saving themselves money in the long term. The “Comparison of 
Non-Microprocessor Knee Mechanism versus C-Leg on Prosthesis Evaluation Questionnaire” 
conducted by the Department of Veterans Affairs is one such study. More extensive data 
focusing on the long term benefits of robotic prosthetics is needed, however. A summary of this 
study can be found in the “Why Microprocessor-Controlled Prosthetics?” section of the 
Background of this report. 
 Hugh was also concerned with the method and means of today’s socket construction by 
prosthetists. He suggested that socket construction could be done with the high resolution MRI 
machines in hospitals, effectively removing the “craft” from socket construction and turning the 
process into more of a science. The MRI machines can be used to create a 3D-model of the 
residual limb. This model can be used to create a perfect socket-fit thus maximizing patient 
comfort and motivation. Hugh, himself, has been doing it this way for years. Many of the 
prosthetists we interviewed still use the traditional method of making plaster molds until one 
feels right to the patient. This process takes time and usually many repeated attempts due to 
imperfections and deformities before an amputee is satisfied with the fit of his socket. And even 
then the socket may still be imperfect. 
In addition to this, Hugh offered that incorporating prosthetist offices into existing 
hospitals could be a much more cost effective approach. Including prosthetists as a department in 
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existing hospitals could greatly reduce the overhead associated with a private office and 
consequently reduce the markup of robotic prosthetic devices.
24
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Interview with Bob Dzuranda12 
Bob Dzuranda has been the president of Biometrics for 14 years. Biometrics is a 
prosthetic-fitting company that employs prosthetists and manages prosthetist offices. Dzuranda’s 
input was invaluable for the construction of the Insurance Contract section in the Background 
Information. The over-the-phone interview that was conducted with him provided this project 
with a perspective on the financial aspects of the prosthetics industry that this project would have 
otherwise severely lacked. 
According to Bob Dzuranda, Medicare and Medicaid paid the lowest amount among 
insurers for prosthetic fee schedules, 15 years ago. Now, however, Medicare usually reimburses 
the prosthetist office more than private insurers will. Because of this, private insurers set 
contracted fee schedules as percentages of the amount that Medicare would have reimbursed the 
company. Unfortunately for the prosthetist offices, it has become a trend for private insurers to 
discount their reimbursement amounts. While reducing the fee schedule reduces overall cost of 
the device, it may not reduce the out of pocket expense from the user because private insurers 
usually do not pay for as large a percent of the fee schedule as Medicare (80%). This trend for 
competitive discounting also hurts the prosthetist office because if the fee schedule is set too low, 
the office will not see enough return. For example, United HealthCare wished to reimburse 
Biometrics 45% less than what Medicare reimburses for prosthetics. United HealthCare would 
then only pay Biometrics $17,197 for a C-Leg that Medicare would pay $31,267 for. It’s difficult 
for a prosthetist company to afford fee schedule cuts, especially when it is hiring more 
administrative staff. Dzuranda reported that he currently employs an approximately equal 
number of clinicians (prosthetists) as front office staff. This is in part because Medicare will not 
hesitate to audit prosthetist offices if it suspects that the prosthetist office has filed a claim 
incorrectly, so it’s crucial for prosthetic companies to have good record keeping. 
Dzuranda recounted a time that his company was audited because a written prescription’s 
authenticity was questioned. Biometrics was not found guilty of anything, but the company did 
have to absorb the cost of all the attorney fees. Another issue is that patients may come in at any 
time or for as many visits after they purchase their prosthetic for no extra cost. 
In response to Hugh Herr’s interest in improving socket fit procedures, Dzuranda was 
asked if he believed Computer Aided Design software and 3D scans would be used more in the 
future. Dzuranda expressed that CAD software will be used to produce sockets more in the future 
and that there may be a negative side to this. 3D scans and CAD software may become more 
popular because they are cost effective, but currently the process is too general and does not 
produce a socket with the most intimate fit. While this is suitable for the majority of amputees, 
those with atypical or traumatic amputations may not get a proper fitting socket. 
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Conclusions 
This section will draw conclusions from the results of our surveys and interviews. We 
will also use this section to highlight some of the main issues addressed in the Discussion section 
of this report. 
 
Prosthetist Survey Conclusions 
One thing that was apparent after conducting the interviews with prosthetists was that 
each had a different approach to treating their patients. Newton-Next Step and Branford-NEOPS 
treated the highest amount of robotic prosthetic users (approximately 50% and 20% of above 
knee amputees, respectively.) Since these prosthetist offices saw a lot robotic prosthetic users, 
they were well prepared to give their patients a temporary robotic prosthetic in case their 
permanent prosthetic broke. These offices were also located in predominantly wealthy areas, 
whereas the prosthetist offices in Worcester and New London did not treat as many robotic 
prosthetic users (about 5% of total amputees used robotic prosthetics). This correlation may 
simply be coincidental, however, because every prosthetist office reported that they had patients 
at one point who had to settle for less functional prosthetics due to cost (Cost to the Patient: 
Question 10.) However, the prosthetists were mostly unsure of the percentage of people who had 
to settle for a different device (Question 11).  
Their uncertainty was most likely due to the manner in which a prosthetist chooses a 
proper prosthetic for his/her patient. If the patient has already been diagnosed as a K2 or below, 
the prosthetist is not going to offer the patient a $45,000 C-Leg because the prosthetist knows 
that the patient’s health insurance will not pay for any fraction of the cost. Since patients are 
dealing with the emotional stress of losing a limb, it would be cruel to offer them a prosthetic 
that their insurance will not cover or that is outside of their budget. This was evident in the 
prosthetists answers to Question 6, where prosthetists from Worcester-NEOPS, Hanger, and New 
London-NEOPS mentioned that low K Level patients are usually not offered or informed about 
robotic prosthetics, since it would just cause the patient more financial stress and grief. In 
response to the same question, 4/5 prosthetists answered that some of their patients who don’t 
use a robotic prosthetic would benefit from one and 1 said his/her patients would probably 
benefit from one. One thing that was very intriguing was that, without prompting them, Newton-
Next Step and New London-NEOPS both stated that K2 Level patients should get access to 
robotic prosthetics. The responses to Question 5 also showed that 4/5 of the prosthetists thought 
that their patients were overall more pleased with robotic prosthetics. 
Four out of the five prosthetists believed that the current prices for prosthetics are 
reasonable; two of them cited research and development as a contributing factor to the high 
prices (Question 14). This agrees with Hugh Herr who reported that $25 million was spent in 
development for the PowerFoot BiOM. The New London-NEOPS prosthetist was unsure of how 
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to answer the question. The prosthetist stated that insurance contracts do not help the patient fund 
their device and that since Medicare covers the largest percent of the cost, patients are sometimes 
forced to quit work and go on disability. When asked if they thought robotic prosthetics will 
become available to the average user, two prosthetists said that prices will decrease (one citing 
the increase in athletic amputees from Iraq and Afghanistan), two thought that prices will remain 
about the same, and the prosthetist from New London was unsure and believed that technological 
advancement is difficult, since billing codes limit designers’ options. 
 
Amputee Survey Conclusions 
 Because of the extremely small sample size of our Amputee Survey, it is impossible to 
draw any meaningful conclusions; however, it can be seen in the Amputee Survey Results 
section of this report that both amputees had similar responses. They both prefer robotic 
prosthetics over tradition prosthetics, they both thought the price of their prosthetic was highly 
unreasonable (having paid thousands of dollars out-of-pocket for their devices), and they both 
have little hope that the cost of robotic prosthetics will be reduced in the future. If the sample 
size of the survey were increased, it’s likely that many amputees would respond similarly.  
Overall, the responses from our amputee survey support the claim that robotic prosthetics 
are out of the financial reach of the average user. The responses to the final question, “With the 
decreasing price of technology in mind, do you think that robotic prosthetics will become 
available to the average user?” were the most revealing. Both responses point at insurance 
companies as the primary cause for the financial troubles that amputees face. As expressed by 
Hugh Herr, these insurance companies would be more willing to payout for robotic prosthetics if 
there was clinical data available that proves that bionics reduce lifetime medical costs.
16
 More on 
this topic can be found in the Interview with Hugh Herr and the Future Work sections of this 
report.  
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Discussion 
In this section, we will discuss many of the major flaws with the financial and other 
aspects of the prosthetic industry. Anecdotes along with information from the background and 
results sections of the report will be integrated to discover exactly what the next step for the 
prosthetic industry should be. 
Prosthetist Survey Discussion 
After completing the interviews with the prosthetists, it was clear that the prices of the 
devices were not as large an issue as initially thought. The prices of the devices are high, but if 
the prosthetists aren’t reimbursed properly, they cannot afford to supply the prosthetics in the 
first place. It seems that the issue lies with getting the proper funding for the device from health 
care providers. Private insurers usually cover less of a percent of the cost than Medicare and they 
usually reimburse the prosthetist office less as well. This can have drastic outcomes for the 
patient, especially if he/she is able-bodied and part of the workforce. Private insurance usually 
will not provide enough money to supply someone with a C-Leg or microprocessor controlled 
prosthetic. For someone who needs to be on their feet at their job, this may mean that they will 
either have to suffer through wearing a less functional prosthetic or quit their job in order to get 
Medicare to cover the device. 
The second main issue is that patients are not offered robotic prosthetics if they do not 
meet the physical requirement as established by Medicare. Since most other insurers require 
patients to be a K3 or K4 functional level as well, it is difficult for patients who suffer from 
obesity, vascular disease, or old age to get a better prosthetic. This issue is discussed further in 
the part of the Discussion entitled “The Issue with Level II Modifiers.” 
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The Issues with Insurance Contracts and L Codes 
   
 Bob Dzuranda and the prosthetist from New London-NEOPS were both very vocal about 
the problems that insurance contracts cause. According to them, it has become a recent trend for 
private insurers to try and reimburse prosthetist offices less and less. Since, Medicare is currently 
the highest payer, most insurance companies set their reimbursement rates as percentages of 
what Medicare pays. Since Medicare is the highest payer though, it’s in their best interest to 
decrease their reimbursement rates, because to the consumer it appears as though Medicare 
charges the most (when in reality they cover a larger percent of the cost than most private 
insurers.) According to the prosthetist from New London, the government is reducing 
reimbursement amounts as well, which causes private insurers reimbursement rates to drop as 
well. While this does decrease the overall total cost, it does not necessarily decrease the out-of-
pocket expense for the patient, and decreased reimbursement rates give prosthetist offices 
decreased incentive to sell robotic prosthetics, since they could make higher profits selling less 
expensive devices. Excessive discounting is the reason why Biometrics cannot serve United 
Healthcare members, since United Healthcare will only reimburse prosthetists 55% of what 
Medicare pays. Since health insurance companies are constantly competing with each other to 
lower their reimbursement rates, the prosthetist companies see less return on investment as time 
passes. In the future, this may lead to denied service to patients that use certain private insurers 
or prosthetist offices will be less inclined to provide expensive electronic prosthetics, since they 
will not profit by offering them. 
 There are also problems with the L-Code application process. Since the process is so 
slow, and hesitant to create new codes for new devices, many times older L Codes are reused for 
newer devices. In some cases, the prosthetist may not be sure what L Code to use. Ottobock 
recommends that a combination of miscellaneous codes and L Codes be used to pay for the C-
Leg Genium, however, the Durable Medical Equipment Medicare Administrative Contractor for 
Region A (the Northeastern United States) prohibits the use of miscellaneous codes for billing 
the C-Leg Genium and recommends that clinicians use the same exact L-Codes to bill the C-Leg 
Genium, as those that are used for the C-Leg. This means that a prosthetist office would only be 
reimbursed $31,267 by Medicare (in CT) for the C-Leg and the C-Leg Genium, even though the 
Genium outperforms the C-Leg and costs nearly twice as much.
6 25
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The Prosthetic Designer’s Dilemma 
 One major hurtle in the prosthetic billing process is the billing categorization process. As 
it stands now, the billing code verification process is time consuming and prevents newer devices 
from entering the market quickly. This process can be seen in the Appendix under HCPCS 
Addition/ Revision Flow Chart. The billing categorization process has the effect of slowing 
down the market for robotic prosthetics. This effect reduces competition and creates a monopoly 
type situation, allowing companies to sell devices at highly marked-up prices for the lack of 
competition. 
The slow pace of the billing categorization process makes it sometimes necessary for 
prosthetists to use existing codes on devices that have yet to be officially categorized. Many 
times these substitute codes do not accurately predict the appropriate costs of the equipment and 
patients or prosthetists are left to make up the difference. Insurance companies also reserve the 
right to audit prosthetist offices for using substitute codes on devices that do not yet have official 
coding. In the audits, the insurance companies may attempt to classify the yet-to-be categorized 
device under the “miscellaneous” category. The insurance payout for miscellaneous devices is 
much lower. Audits can leave prosthetist offices with large legal fees like the ones Biometrics 
had to face when the authenticity of a prescription came under question.
12
 These legal fees and 
audits further increase the mark-up of the prosthetics sold by prosthetists, which further 
decreases the availability of robotic prosthetics. These issues make it next to impossible for 
designers to introduce their products into the prosthetic market before official L-codes are 
established. Paradoxically, the HCPCS application has volume and marketing requirements that 
must be met before L-codes can be established and a need for a new code must be recognized by 
Medicare, Medicaid, or a national private insurance company.
26 
Furthermore, the process stifles development in that it is easier for engineers to produce 
and market prosthetics that operate and function similarly to devices that have already been 
assigned L codes than it is for them to produce new, better, and potentially “bionic” technology. 
Financial trouble can arise if a product that was intended by the developer to receive a new L-
code (and with it a new fee schedule) is instead lumped into an existing L-code. The price of the 
device will be equal to the other devices under the same L code and it may be difficult to receive 
a viable return on the investment that was made to produce the device, since, as can be seen in 
The Issues with Insurance Contracts and L Codes section, it may be impossible for prosthetists to 
offer a device to their patients if the fee schedule is too low. 
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The Issues with Level II Modifiers (K-Levels) 
The current Level II Modifiers (K-Levels) system is effective at its goal of predicting the 
appropriate type of equipment for each unique amputee; however, the way that the K level 
system is used by insurance companies to deny the use of robotic prosthetics to amputees whom 
could potentially benefit greatly from the use of them is seriously flawed and morally wrong. 
Data collected as part of our background research and as part of our prosthetist interviews 
supports this claim. 
The best treatment for diabetes is an active life style and a well controlled diet. When 
these things fail, lower extremity amputation can sometimes be unavoidable. Allowing diabetic 
amputees access to robotic prosthetic technology can be key to motivating them to improve their 
lifestyle and become more active; however, diabetic amputees often get placed into k level 2 and 
below as a result of their condition, effectively banning them from robotic prosthetic use. 
According to People with Amputation Speak Out, up to 55% of diabetic amputees require the 
amputation of the second leg within 2-3 years of the first amputation.
7
 It is likely that many of 
these repeat amputations could be avoided if the patients are given the technology that would 
allow them and potentially motivate them to become more active and therefore healthier.  
Additionally, the K level system how it currently stands restricts the market for many 
expensive robotic prosthetics. Allowing select K2 patients the use of robotic prosthetics would 
effectively expand the customer base and increase demand. This increased demand could lead to 
price drops for future amputees. In the study, “Comparison of Non-microprocessor Knee 
Mechanism versus C-Leg on Prosthesis Evaluation Questionnaire”, 4 out of the 9 K2 Level 
subjects were able to increase their activity level to a K3 through the use of a microprocessor 
knee.
8 
Aside from diabetic patients, two of the prosthetists we interviewed agreed that many of 
their other K level 2 patients would benefit from the use of a robotic prosthetic as seen in the 
answers to question 6 “Do you think some of your patients who do not use a robotic prosthetic 
would benefit from one?” which can be found in the Prosthetist Survey Data section of this 
report.  
 “Comparison of Non-microprocessor Knee Mechanism versus C-Leg on Prosthesis 
Evaluation Questionnaire” is a study performed by the Department of Veteran’s affairs. The 
study had some interesting findings about the K level system as seen in the following excerpt,  
 
 
 
 
 37 
 
 
“Using only the strict MFCL performance ratings typical in the 
clinical setting, the clinician in this study initially rated 9 of the 19 
subjects as MFCL K2; these subjects would not have been considered 
MKM candidates. Of these nine subjects, four (47%) increased their 
MFCL from K2 to K3; thus, amputees who according to MFCL guidelines 
would not have been candidates for the C-Leg actually improved their 
functional performance when using the C-Leg. Specifically, we found that 
not only are limited community G1 (MFCL K2) candidates for MKM 
technology, they are also able to advance to the MFCL K3 level when 
prescribed an MKM. In summary, our findings support that costly high-
tech components may be under-prescribed [46]. This finding is exemplary 
of why amputees should be provided the opportunity to use the most 
advanced technology that could potentially increase their function.”8 
The Amputee Mobility Predictor Tool is designed to be performed with or without the use of a 
prosthetic.
34
 The excerpt above explains that four of the subjects in the study were able to 
increase their assessed K-level from K2 using their non-robotic prosthetic to K3 by using the C-
Leg provided by the clinicians. The data strongly suggests that many K2 amputees are unfairly 
restricted and would greatly benefit from the use of robotic prosthetics. 
 The K-level system should be used only as a predictor of the appropriate equipment an 
amputee should receive, not as a final judgment. The final say should be up to the patient and the 
prosthetist and should depend on the patient’s willingness and ability to operate robotic 
prosthetic devices. In this way, treatment of amputees can be both fair and effective. 
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Need for Parity Laws 
Both Maryland’s SB 98 (2008), Prosthetic Parity Act, and the amputee Coalition of 
America’s “Analysis of Assembly Bill 2012-Amended: Orthotic and Prosthetic Devices” 
underline many of the reasons why medical insurance parity laws are necessary and how they 
could potentially affect the prosthetic industry. 
The medical insurance parity laws directly affect prosthetist company insurance contracts 
as stated in the Parity Laws section of the Background. The overall effect of parity laws will be 
to increase the number of individuals with access to robotic prosthetics. The “Analysis of 
Assembly Bill 2012-Amended: Orthotic and Prosthetic Devices” conducted by the Amputee 
Coalition of America, which can be found in the appendix, outlines the reasons why increasing 
the availability of prosthetics is beneficial. The report highlights financial, social, and medical 
benefits of prosthetic devices.  
Forcing private insurers to use the same fee schedule as Medicare does not mean that 
those private insurers will reimburse prosthetists the same amount of money as Medicare does. 
Medicare has a coinsurance of 20%. This means that Medicare covers 80% of the fee schedule 
cost and the user must cover the remaining 20%. Private insurers can have varying coinsurance 
rates as well as coinsurance and out-of-pocket maximums and therefore the actual payout by the 
insurance company can still vary. However, under the prosthetic parity laws, if the same device 
was purchased in the same year by two different amputees from the same billing region, amputee 
X with Medicare, and amputee Y with a private insurer, then the amount that amputee X must 
pay plus the amount that Medicare must pay will equal the amount that amputee Y must pay plus 
the amount that his private insurance must pay. As a result, the prosthetist office will be 
reimbursed an equal amount for the two same prosthetics regardless of the insurer. This will 
allow prosthetists to offer robotic prosthetics to more of their patients, thus potentially increasing 
the demand for these devices and decreasing the price while increasing the overall availability. 
Designers of robotic prosthetics will also benefit since their products can be offered to a larger 
population. 
A significant argument in favor of parity laws is the fact that requiring private insurance 
to use the same fee schedules as Medicare will increase premiums by only $0.12-$0.35 per 
month ($1.44 - $4.20 per year) per policy holder according to research presented in “Analysis of 
Assembly Bill 2012-Amended: Orthotic and Prosthetic Devices.”27 Since this is the case, the 
benefits of parity acts far outweigh the costs, since more privately insured individuals would 
have better access to prosthetics. 
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Future Work 
This section will discuss the future work that we believe should be done in order to 
increase the availability of robotic prosthetics. 
Surveys and Studies 
“Amputee Patient Comfort and Compliance” and “People with Amputation Speak Out” 
are two extensive surveys that were conducted in part by the Amputee Coalition of America in 
order to better understand the physical, social, and psychological strains that amputees face. The 
survey results have one major downfall; they do not distinguish between the users of robotic 
prosthetics and the users of traditional prosthetics. Similar if not identical studies should be 
conducted that do make the distinction. Included in these surveys should be questions aimed 
specifically at K2 and below amputees whom do not use robotic prosthetics. The questions 
should ask whether or not the amputees feel that they would benefit from the use of robotic 
prosthetics. 
Additional studies should be conducted on the diabetic population. Specifically, the 
studies should answer whether or not diabetic amputees given robotic prosthetics are more or 
less likely to require the amputation of the second limb over diabetic amputees given traditional 
prosthetics. It should also answer whether or not the life expectancy of diabetic amputees is 
affected by the use of robotic prosthetics. Overall, the study should answer whether or not 
diabetic amputees given robotic prosthetics live healthier (and less medically costly) lives as 
compared with diabetic amputees given traditional prosthetics. 
Free Market 
 For most electronic devices available, it is possible to purchase recertified or refurbished 
devices at a significant cost reduction. Why should prosthetics be any different? Old robotic 
prosthetics that have reached the end of their warranty could be bought back by the designing 
company (or used toward credit on the newer model) and then refurbished. These recertified 
devices could be sold at a lower rate (but still for a profit) to those whom cannot afford the most 
updated technology. 
 Websites such as newegg.com are known for their accurate specifications and extensive 
user reviews and ratings of the merchandise they sell. This idea can be brought to the robotic 
prosthetic industry. It would be possible for Medicare or a third party to run a website based on 
the Medicare fee schedules. Robotic prosthetics and other prosthetic components would be 
searchable by category, name, or L-code. Each Device would have a list of standardized 
specifications and a section for user reviews and ratings of the equipment. The site may also 
include searchable databases for medical insurance providers and Prosthetists. Users would be 
encouraged to rate and/or review their insurance provider and prosthetist as well as their 
prosthetic. 
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Prosthetist Hospital Integration 
 Integrating prosthetist offices into existing hospitals would have several benefits. 
Firstly, prosthetists would gain access to MRI imaging technology for producing computer 3D-
modeled sockets for their patients.24 A better fitting socket can lead to an increased level of 
comfort, motivation, activity and consequently better overall health. Secondly, the integration of 
prosthetist offices into existing hospitals would allow the prosthetists to sell robotic and 
traditional prosthetics at a lower markup due to decreased overhead and administrative costs, 
thus making the devices more accessible to lower income patients.  
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Appendix 
HCPCS Code Addition/ Revision Application Form 
Healthcare Common Procedure Coding System (HCPCS)  
Alpha-Numeric Coding Recommendation Format for the 2014 Update  
Instructions:  
1. Please sign and date each recommendation. Be certain to provide the name, complete address and direct 
telephone number of the person to be contacted regarding this recommendation. We use this information to 
contact applicants regarding upcoming meetings, questions regarding applications, and to make notifications of 
the status of applications. Please be sure that your system can receive emails from cms.hhs.gov.  
2. Please provide documentation of the item's current classification by the Food and Drug Administration (FDA). 
Include a copy of the cover page from the initial FDA application and a copy of the FDA's determination, 
notification/approval letter. If the  
Drug/biological/product/service has been subject to an assessment by any other agency or recognized 
medical body, provide a copy of the results of that assessment. Note: Documentation of FDA approval of a 
drug or biological may be submitted after the coding application but no later than March 31, 
provided
 all other 
requested information is complete and submitted by the deadline.  
3. Please note: All requested information must be supplied before your recommendation for modifications to 
the HCPCS coding system can be considered.  
The following questions may be transferred to a word processor/computer to allow space to respond fully and 
completely. All questions must be answered. "N/A" is not an acceptable response. If the question does not appear 
to apply, provide a detailed explanation as to why it doesn't apply. Incomplete submittals will not be accepted.  
4. Submit Coding Recommendations to:  
Felicia Eggleston, CMS HCPCS Workgroup Coordinator Centers for Medicare and Medicaid Services C5-08-27 
7500 Security Blvd Baltimore, Maryland 21244-1850  
Alpha-Numeric HCPCS Coding Recommendation Format INFORMATION SUPPORTING CODING 
MODIFICATION RECOMMENDATION  
1. For the purpose of publication on our request list and public meeting agenda on the HCPCS website, please 
provide a brief summary of your request (not to exceed 300 words). In this summary, please specify your 
request to modify the HCPCS code set:  
(e.g. number of new codes requested, recommended language; revise a code (provide old language and 
recommended language), discontinue a code). Include the name of the product, description, function, and the 
reason why existing codes do not adequately describe your product. For drugs, include the indications for use, 
action, dosage and route of administration, and how supplied. Text that exceeds the 300-word limit may be 
truncated and not appear on our published summary, therefore, it is important to provide a concise summary within 
the 300-word limit. CMS may edit your summary prior to publication.  
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2. Identify the Item (product or drug/biological) for which a Level II HCPCS Code is being requested. A) Trade or 
Brand Name: B) General Product Name or Generic Drug Name (active ingredient): C) FDA classification:  
3. Please check one HCPCS category from the following list, which most accurately describes the item identified in 
question #1:  
__ A) Medical/Surgical Supplies __ B) Dialysis Supplies and Equipment __ C) Ostomy/Urological Supplies __ D) 
Surgical Dressing __ E) Prosthetic __ F) Orthotic __ G) Enteral/Parenteral Nutrition __ H) Durable Medical 
Equipment __ I) Blood/Blood Products __ J) Drug/Biological __ K) Radiopharmaceutical __ L) Vision __ M) 
Hearing __ N) Other (please indicate/provide category)_________________________________  
4a.) Is the item durable, if so, explain how it can withstand repeated use?  
Specify whether the entire item or only certain components of the item can withstand repeated use:  
4b.) If the entire item can withstand repeated use, then please specify the length of the  
time that the item can withstand repeated use. 4c.) If only certain components of the device can withstand 
repeated use, then please identify the individual components and the length of the time that the individual 
components can withstand repeated use. 4d.) Please provide detailed information on the warranty of the device such 
as the parts included under the warranty, the length of the warranty and the parts excluded from the warranty. In 
addition, please specify if the device includes any disposable components and the expected life or the replacement 
frequency recommended for the disposable components.  
1. Describe the item fully in general terminology. What is it? What does it do? How is it used? Describe the 
patient population for whom the product is clinically indicated. Descriptive booklets, brochures, package 
inserts, as well as copies of published peer-reviewed articles on the item may be included in the information 
packet submitted for review, but they do not replace the requirement to fully respond to this question and fully 
describe the item. For drugs and biologicals, include: A) indications for use, B) action, C) dosage and route of 
administration, D) package insert and, E) how supplied.  
2. Describe how the item/product is primarily and customarily used to serve a medical purpose.  
7A) Identify similar products and their manufacturers. (If a drug -list other drugs by trade name marketed under the 
same active ingredient category/generic name.) 7B) Identify significant differences between this item and other 
products listed above. (Include differences in item cost; material; product design; how it is used; different 
mechanism of operation, differences in function/treatment provided to a patient; clinical indication; and clinical 
outcome.) 7C) Complete item 7C only if you are making a claim of significant therapeutic distinction). Claims of 
significant therapeutic distinction when compared to the use of other, similar items, must be described in detail. 
Articulate the clinical theory behind the claim, including differences in the product or its operation as it compares to 
currently coded products. Specify how the product results in a significantly improved medical outcome or 
significantly superior clinical outcome. (Please refer to the HCPCS decision tree for additional information.) Provide 
the best available information related to your claim. Include copies of all articles that result from your systematic 
analysis of the available literature. Information submitted should be as complete as possible. Unfavorable articles 
should be provided with any appropriate rebuttal or explanation. If the articles submitted cause you to exceed the 
overall 40-page limit, then submit one reference copy of each article and 35 copies of the application.  
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Answer each of the questions A), B), and C) below: A) List any 3
rd 
party payers that pay for this product B) List any 
codes that are currently being billed to those payers for this product.  
C) Explain why existing code categories are inadequate to describe the item.  
9. A) Is this product prescribed by a health care professional? B) If yes -who prescribes the product and in what 
setting(s) is the product prescribed?  
10. A) Is the item useful in the absence of an illness or injury? B) Explain:  
11a.) Provide the date that the item/product was cleared for marketing by the FDA. If the product is exempt from 
FDA review and classification, please explain the basis for the exemption.  
b.) Attach copy of the FDA approval letter including the 510(k) summary for those items that are approved using the 
510(k) process. Also, if an item is cleared using the 510(k) process, identify the HCPCS codes, if 
applicable, that describe the predicate products listed in the 510(k) submission and explain why these codes 
do not adequately describe the item that is the subject of the HCPCS recommendation. In other words, if an 
item is listed as being substantially equivalent to another item(s) in an application for FDA marketing 
clearance, why is it not equivalent or comparable for coding purposes?  
c.) For drugs and biologicals only: In order for an application for a code for a drug/biological can be considered 
timely and complete: FDA approval documentation may be submitted after the code application, but no 
later than March 31, 2013, provided all other application materials are complete and submitted by the 
deadline of January 3, 2013, and provided the application for marketing approval has been submitted to 
the FDA by September 30, 2012. Applicants awaiting FDA clearance for drugs or biologicals at the 
January 3
rd 
submission deadline must submit with the application documentation evidencing submission 
for FDA approval, along with the date the application was submitted to the FDA.  
12A) When was the item/product marketed in the United States?  
Note For drugs and biologicals, the date of first sale is required.  
12B) For all items that are not drugs and not biologics, the applicant must submit 3 months of marketing experience 
following the FDA approval date. For the 3 months prior to submitting this coding recommendation, what is the 
total number of units sold in the U.S. and the total dollar amount in sales (Medicare, Medicaid  
and private insurance)? Do not estimate or provide projections -the information  
provided must represent actual volume of sales for the product for the period of time  
indicated. Note: For drugs and biologicals, information regarding the number of units  
sold is not required.  
13. Identify the percent of use of the item across the following settings. For drugs/biologicals, provide the 
percentage of use for the setting in which this product is or would be administered.  
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Physician's Office: _______  
Freestanding Ambulatory Care Clinics: _______ Patient's Home by patient: _______ Patient's Home by Health Care 
Provider: _______ Nursing Home/Skilled Nursing Facility: ________ Hospital Inpatient Facilities: ________ 
Hospital Outpatient Facility: ________ Other-(identify): _________ TOTAL VOLUME OF USE ACROSS ALL 
SETTINGS SHOULD EQUAL 100%  
14. What is the Manufacturer’s Suggested Retail Price (MSRP) or list price of the item?  
This question must be answered for all items, except drugs/biologicals.  
 
HCPCS Coding Recommendation submitted by:  
* Please provide a complete mailing address and direct dial phone number. We use this information to contact 
applicants regarding upcoming meetings, questions regarding applications, and to make notifications of the status of 
applications.  
Name: Name of Corporation/Organization: Mailing Address (street): City, State, Zip Telephone Number 
and extension: FAX Number: E-Mail Address:  
I attest that the information provided in this HCPCS coding recommendation is accurate and correct to the best of 
my knowledge.  
____________________________ _________________________Date:_____________  
Signature of Applicant  
Is applicant the manufacturer? Y/N If not, the manufacturer must sign the following attestation:  
I attest that the information describing the product is accurate. ____________________________ 
_________________________Date:_____________  
Signature of Manufacturer  
According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of 
information unless it displays a valid OMB control number. The valid OMB control number for this information 
collection is 0938-1042. The time required to complete this information collection is estimated to average 11 hours 
per response, including the time to review instructions, search existing data resources, gather the data needed, and 
complete and review the information collection. If you have comments concerning the accuracy of the time 
estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA 
Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850. 
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HCPCS Revision/Addition Flow Chart  
Figure 4: HCPCS Revision/Addition Flow Chart (cms.gov) 
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Definitions and Clarifications of HCPCS Flow Chart 
Tier 1:  
HCPCS 2 is the appropriate code jurisdiction: Item is not within the jurisdiction of CPT, CDT, ICD or 
DRG coding.  
Primarily Medical in nature: Item is primarily and customarily used to serve a medical purpose and is not 
useful in the absence of a medical condition or injury.  
FDA approved if regulated: See the online Medicare Benefit Policy Manual #100.2, Chapter 15 – 
Covered Medical and Other Health Service, Section 50.4.1 – Approved Use of Drug. Does not apply if 
regulated items are not yet approved. Note: FDA approval for drugs accepted up to 90 days after the 
application deadline.  
National Programmatic Need: At least one insurance sector, public (Medicare or Medicaid) or private 
(commercial insurers) identified a program operating need to separately identify the item and that need is 
common across the sector, (i.e., nationally, as opposed to one or a handful of individual insurers or 
states). Does not apply if item identification is statutorily required.  
Tier 2:  
Existing or similar code: Describes a similar function to previously coded products  
Volume and marketing criteria: There must be sufficient claims activity or volume (3% of affected 
population), as evidenced by 3 months of marketing activity for non-drug products, so that the adding of a 
new or modified code enhances the efficiency of the system and justifies the administrative burden of 
adding or modifying a code and establishing policy and system edits.  
Note: Marketing data requirements waived for drugs only.  
Performs a different function: Does something completely different to the patient. Examples: suction for a 
different purpose; static vs. dynamic; swing vs. stance.  
Operates differently: Performs the same or similar function to other items, using a different mechanism. 
Examples: mechanical vs. electronic; automatic vs. manual regulating; extrinsic vs. intrinsic lubrication.  
Significant Therapeutic Distinction: Improved medical benefit when compared with the use of other, 
similar items, e.g., significantly improved medical outcome or significantly superior clinical outcome. 
Requests for modifications to the HCPCS Level II code set based on such claims are reviewed on a case-
by-case basis, taking into consideration clinical information provided by the applicant and other 
commentators that supports or refutes the claim(s) made by the applicant. In submitting a request, an 
applicant should provide the best available information supporting his or her claim. Greater weight will be 
given to more methodologically rigorous and scientifically reliable evidence. Note that process indicators 
(such as improved compliance, convenience and personal preference) are considered significant 
distinctions only to the extent that they result in demonstrably improved clinical outcomes.  
Revised: October 16, 2006  
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Some Health Insurance Quotes 
 
Table 5: Aetna Health Insurance Quotes15 
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Table 6: Assurant Health Insurance Quotes28 
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Table 7: Anthem Blue Cross Blue Shield Health Insurance Quotes13 
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Medicare 
Plan Category Costs 
Part B 
Deductable $140  
Coinsurance Maximum N/A 
Max Out-of-Pocket N/A 
D.M.E 20% of the Medicare 
approved cost plus the 
difference between the 
approved cost and the 
actual cost. 60 visits per 
year for physical therapy 
Specialist Visit 
Physical Therapy 
  
Table 8: Medicare Coverage14 
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A Description of each K Level and the Amputee Mobility Predictor Tool 
 
 
K-Level 0 
 
Does not have the ability or potential to ambulate or transfer safely with or without 
assistance, and a prosthesis does not enhance quality of life or mobility. 
 
 
K-Level 1 
 
Has the ability or potential to use a prosthesis for transfers or ambulation in level 
surfaces at a fixed cadence. Typical of the limited and unlimited household 
ambulator. 
 
 
K-Level 2 
 
Has the ability or potential for ambulation with the ability to transverse low-level 
environmental barriers such as curbs, stairs, or uneven surfaces. Typical of the 
limited community ambulator. 
 
 
K-Level 3 
 
Has the ability or potential for ambulation with variable cadence. Typical of the 
community ambulator who has the ability to transverse most environmental 
barriers and may have vocational, therapeutic, or exercise activity that demands 
prosthetic use beyond simple locomotion. 
 
 
K-Level 4 
 
Has the ability or potential for prosthetic ambulation that exceeds basic ambulation 
skills, exhibiting high impact, stress, or energy levels. Typical of the prosthetic 
demands of the child, active adult, or athlete. 
 
 
Table 9: Description of K Levels29 
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Table 10: The Amputee Mobility Predictor Tool29 
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Analysis of Assembly Bill 2012-Amended: Orthotic and Prosthetic Devices 
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Prosthetic Designers/Manufacturers Interview Questions 
 
Please answer the following to the best of your ability. If at any point you feel 
uncomfortable answering a question, you may feel free to skip it.  
Customer Base 
 
1. Approximately how many people use the name of device? 
 
2. What companies purchase the name of device? 
 
3. Approximately how many companies purchase the name of device? 
 
How much do companies pay for each name of device? 
 
Costs 
4. Approximately how much do the components and materials in each name of device cost? 
 
5. Approximately what does it cost to manufacture and assemble each name of device? 
 
6. Approximately what percent of each name of device's cost goes towards paying employees? 
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Research and Development 
7. What kind of equipment did you use in order to test the name of device? 
 
8. How much did it cost? 
 
9. Did you get investors in order to help fund the R&D or manufacture of the name of device? 
 
10. If so how much did they contribute? 
 
Patents 
11. Did you purchase a patent for the name of device? 
 
12. Did you obtain investors in order to purchase your patent? 
 
13. If so how much did they invest? 
 
FDA 
14. Did your company face any losses during the FDA approval process? 
 
15. What's the Future for Prosthetics? 
 
16. With the decreasing price of technology in mind, do you think that robotic prosthetics will 
become available to the average user? 
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Robotic Prosthetic User Survey 
 
https://docs.google.com/spreadsheet/formResponse?pli=1&formkey=dDk1bGNXTVdoM1JWRi
15Yk5qWjU2OFE6MQ&ptok=4035386664722204212&ifq 
Please only fill out this survey if you currently use, or have previously used, a robotic prosthetic 
device. For the purpose of this project, any electronically powered prosthetic is considered 
robotic. A few examples include the C-Leg, Rheo Knee, i-Limb, Proprio Foot, and myoelectric 
prosthetics. I am part of a project team at Worcester Polytechnic Institute that is currently 
investigating the high prices of robotic prosthetics. I would be extremely pleased if you filled out 
the following survey, so that my team and I might gain a better perspective on the financial 
challenges amputees face. Your responses will be kept completely anonymous.
 
1. Please specify your level of amputation.  
 
2. What is the name of the robotic prosthetic you use/have used? 
  
3. Would you rather use a traditional prosthetic or a robotic one?  
Why? 
 
4. Are you pleased with the function of your robotic prosthetic?  
Why?  
 
5. Do you feel there is a prosthetic that would better suit your needs?  
 
6. If so, please give a description or the name of the prosthetic.  
 
7. Was price a major factor when choosing your robotic prosthetic?  
 
 
 
8.  If so, how did it affect your decision? 
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Prosthetic Price 
 
9. What was the total out-of-pocket expense for your prosthetic? How much did you 
personally pay?  
 
10. What was the total cost of your robotic prosthetic? How much would it have cost you 
without health insurance or other aid?  
 
11. What health insurance provider did you have when you purchased your prosthetic?  
 
12. Approximately what percent of the cost did your health insurance cover?  
 
13. If you received any other financial aid, who provided it? Type the names of any sources 
of aid you received. (Veteran's Affairs, Barr Foundation, Limbs for Life, etc.)  
 
14. If you received any other financial aid, how much of the cost did it cover?  
 
15. On a scale of 1-5, was the price of your robotic prosthetic reasonable or unreasonable?  
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Physical Therapy and Associated Costs 
 
16. What was the total out-of-pocket expense for your physical therapy?  
 
17. If you required physical therapy, what was the total cost? How much would it have cost 
you without health insurance or other financial aid?  
 
18. Approximately what percent of the cost did your health insurance cover?  
 
19. If you received any other financial aid, how much of the cost of physical therapy did it 
cover?  
 
 
 
 
Warranty 
 
20. How long is the warranty for your robotic prosthetic?  
 
21. What's the average amount of time you use a robotic prosthetic for before it needs to be 
replaced or repaired?  
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Amputee Survey Flyer 
Are you paying too much for 
your robotic prosthetic? 
 
 My project group at Worcester Polytechnic Institute 
is currently investigating the high prices of robotic 
prosthetics. 
My group partners and I are collecting survey data and 
conducting interviews with amputees, health insurance 
representatives, prosthetists, and manufacturers, in order 
to find a means for reducing the cost of these prosthetics. 
 
 Your help would be greatly appreciated in aiding this 
effort. We would love to hear about any of your 
experiences with your robotic prosthetic and we would be 
grateful if you would be willing to answer a brief 
questionnaire. Any data collected will be kept strictly 
anonymous. 
 
 
Contact me at: 
herpderpherpderp 
herpderpinderpderpin 
 
Daniel Topping 
Worcester Polytechnic Institute 
Biomedical Engineering 
Class of 2013 
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